Clinical Trial Update: Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma [NA]

View source ↗

Summary

This clinical trial update describes a study investigating EGFR mutation–guided second-line therapy for patients with advanced lung adenocarcinoma, a form of no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Snippet

Sponsor: National Cheng-Kung University Hospital | Conditions: Non-Small Cell Lung Cancer | NA | Status: UNKNOWN